End-of-day quote
Other stock markets
|
||
- USD | - |
|
Jul. 02 | Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc. Appoints Patricia Drake as Chief Commercial Officer | CI |
Jun. 18 | Cantor Fitzgerald Initiates Innoviva at Overweight Rating | MT |
Chart calendar Theravance Inc
Upcoming events on Theravance Inc
Past events on Theravance Inc
2024-06-17 11:00 am | Annual General Meeting |
2024-06-10 01:20 pm | Goldman Sachs Global Healthcare Conference |
2024-05-15 12:20 pm | BofA Securities Health Care Conference |
2024-05-08 04:05 pm | Q1 2024 Earnings Release |
2024-04-30 02:30 am | European Society of Clinical Microbiology and Infectious Disease Global Congress - Poster No - 246 |
2024-04-29 06:00 am | European Society of Clinical Microbiology and Infectious Disease Global Congress - Poster No - 1421 |
2024-04-29 06:00 am | European Society of Clinical Microbiology and Infectious Disease Global Congress - Poster No - 1281 |
2024-04-29 06:00 am | European Society of Clinical Microbiology and Infectious Disease Global Congress - Poster No - 1816 |
2024-04-28 06:00 am | European Society of Clinical Microbiology and Infectious Disease Global Congress - Poster No - 2527 |
2024-04-28 06:00 am | European Society of Clinical Microbiology and Infectious Disease Global Congress - Poster No - 2424 |
2024-04-28 06:00 am | European Society of Clinical Microbiology and Infectious Disease Global Congress - Poster No - 2724 |
2024-02-29 04:05 pm | Q4 2023 Earnings Release |
2023-11-01 04:15 pm | Q3 2023 Earnings Release |
2023-10-14 12:15 pm | IDWeek Conference - Poster No:2517 |
2023-10-14 12:15 pm | IDWeek Conference - Poster No:2515 |
2023-10-14 12:15 pm | IDWeek Conference - Poster No:2526 |
2023-10-14 12:15 pm | IDWeek Conference - Poster No:2121 |
2023-10-14 12:15 pm | IDWeek Conference - Poster No:2133 |
2023-10-14 12:15 pm | IDWeek Conference - Poster No:2132 |
2023-10-14 12:15 pm | IDWeek Conference - Poster No:2138 |
Annual results
Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 261 257 1.38% | 337 261 29.25% | 392 292 34.12% | 331 338 -1.83% | 310 300 3.44% | 303 |
EBITDA Million USD | Released Forecast Spread | 260 255 2.13% | 335 246 36.13% | 389 274 42.09% | 221 229 -3.42% | 0,00 144 - | 116 |
EBIT Million USD | Released Forecast Spread | 246 242 1.9% | 321 245 31.1% | 375 273 37.64% | 207 218 -5.11% | 136 116 17.25% | 101 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 233 229 1.7% | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
Net income Million USD | Released Forecast Spread | 157 156 0.83% | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
EPS USD | Released Forecast Spread | 1,43 1,38 3.62% | 0,00 0,00 - | 0,00 0,00 - | 2,37 0,85 178.82% | 0,00 0,00 - | 0,00 |
Announcement Date | 05/02/20 | 03/02/21 | 09/02/22 | 28/02/23 | 29/02/24 | - |
Quarterly results
Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 90,1 86,4 4.23% | 108 215 -49.61% | 67,3 200 -66.45% | 65,8 58,9 11.81% | 76,4 62,0 23.16% | 81,0 67,9 19.25% | 67,3 75,7 -11.1% | 85,8 75,5 13.67% | 77,5 68,0 13.96% | 74,7 | 70,9 | 79,9 |
EBITDA Million USD | Released Forecast Spread | 86,1 47,5 81.36% | 27,9 37,8 -26.07% | 25,6 39,7 -35.5% | 38,8 35,9 8.01% | ||||||||
EBIT Million USD | Released Forecast Spread | 82,6 325 -74.61% | 22,5 173 -87.01% | 24,2 21,0 14.96% | 29,9 23,9 25.12% | 33,5 22,8 46.61% | 17,9 24,7 -27.44% | 44,0 24,1 82.93% | 32,2 20,6 56.28% | 26,0 | 19,4 | 26,8 | |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 286 34,9 720.7% | 41,1 23,3 76.57% | ||||||||||
Net income Million USD | Released Forecast Spread | 266 27,0 883.42% | 34,9 19,4 79.72% | ||||||||||
EPS USD | Released Forecast Spread | 2,80 0,31 803.23% | -0,98 0,29 -437.93% | 0,42 0,23 82.61% | |||||||||
Announcement Date | 27/04/22 | 27/07/22 | 09/11/22 | 28/02/23 | 09/05/23 | 02/08/23 | 01/11/23 | 29/02/24 | 08/05/24 | - | - | - |
2024-07-15 | CAMURUS AB: Q2 2024 Earnings Release |
2024-07-16 | GLAND PHARMA LIMITED: Q1 2025 Earnings Release (Projected) |
2024-07-17 06:45 am | JOHNSON & JOHNSON: Q2 2024 Earnings Release |
2024-07-17 | JUBILANT PHARMOVA LIMITED: Q1 2025 Earnings Release (Projected) |
2024-07-18 01:00 am | NOVARTIS AG: Q2 2024 Earnings Release |
2024-07-18 | TEYI PHARMACEUTICAL GROUP CO.,LTD: Q2 2024 Earnings Release |
2024-07-21 | GLAXOSMITHKLINE PHARMACEUTICALS LIMITED: Q1 2025 Earnings Release (Projected) |
2024-07-21 | ALMIRALL, S.A.: Q2 2024 Earnings Release |
2024-07-22 | TORRENT PHARMACEUTICALS LIMITED: Q1 2025 Earnings Release (Projected) |
2024-07-23 | INNOVIVA, INC.: Q2 2024 Earnings Release (Projected) |
Past sector events for Theravance Inc
2024-07-10 | HISAMITSU PHARMACEUTICAL CO., INC.: Q1 2025 Earnings Release |
2024-07-09 | LOTUS PHARMACEUTICAL CO., LTD.: June 2024 Sales and Revenue Release |
2024-07-09 07:35 am | SCINOPHARM TAIWAN, LTD.: June 2024 Sales and Revenue Release |
2024-07-03 | HISAMITSU PHARMACEUTICAL CO., INC.: Q1 2024 Earnings Release (Projected) |
2024-07-02 05:05 am | ONENESS BIOTECH CO., LTD.: June 2024 Sales and Revenue Release |
2024-06-21 11:28 am | DEVA HOLDING: Q1 2024 Earnings Release |
2024-06-13 05:21 pm | EIS ECZACIBASI ILAÇ, SINAI VE FINANSAL YATIRIMLAR SANAYI VE TICARET: Q1 2024 Earnings Release |
2024-06-11 01:30 am | BORA PHARMACEUTICALS CO., LTD.: June 2024 Sales and Revenue Release |
2024-06-07 06:33 am | SCINOPHARM TAIWAN, LTD.: May 2024 Sales and Revenue Release |
2024-06-07 05:17 am | LOTUS PHARMACEUTICAL CO., LTD.: May 2024 Sales and Revenue Release |
- Stock Market
- Equities
- INVA Stock
- Stock
- Calendar Theravance Inc